
Collaboration - June 5, 2015
Biogen Files MAA for Hemophilia Drug
Swedish Orphan Biovitrum AB (Sobi’s) partner Biogen has submitted a Marketing Authorisation Application (MAA) for Alprolix (rFIXFc) to the European Medicines Agency (EMA). Sobi has an opt-in right to assume final development and commercialization of Alprolix in Europe, Russia, certain countries in the Middle East, and North Africa, according to Sobi. The MAA filing with […]

Pharma Business - May 5, 2015
Novo Opening New Facility
Novo Nordisk broke ground May 4 on a new 7,500 m2 manufacturing facility in Kalundborg, Denmark. The company is investing 1.5 billion Danish kroner in the facility, which will produce active pharmaceutical ingredients for NovoSeven®and future products for treating hemophilia. The investment is estimated to create 100 new production and engineering jobs in Kalundborg, where […]

Companies - April 2, 2015
Support for Hemophilia Patients
Novo Nordisk has launched a comprehensive patient support program, NovoSecure, for people with hemophilia. Eligible patients can apply for assistance including career counseling and HeroPath life coaching, which are specifically tailored to help patients address the often overlooked aspects of living with a chronic disease. NovoSecure was created as a result of information obtained through […]

Uncategorized - March 18, 2015
New Findings Could Help Hemophiliacs
An international research project has shown evidence that exposing embryos to medication to control bleeding from hemophilia reduces the chance of the immune system developing resistance to it later. “As a result, the immune system will ‘think’ later in life that the medicine is part of the body’s innate functionality and so it will continue […]